Beneficial effect of combined 3,5,3'-triiodothyronine and vasopressin administration of hepatic energy status and systemic hemodynamics after brain death.
The influence of combined replenishment of L-3,5,3'-triiodothyronine (T3) and vasopressin (antidiuretic hormone [ADH]) on both hepatic metabolism and systemic hemodynamics was assessed in brain-dead dogs. Arterial ketone body ratio (AKBR) was measured as a parameter of hepatic metabolism, which reflects the redox state (free nicotinamide adenine dinucleotide/reduced nicotinamide adenine dinucleotide) of liver mitochondria. Mean arterial blood pressure (MAP) was significantly decreased from 110.4 +/- 3.8 to 44.4 +/- 1.7 mmHg, at 1 hr after completion of brain death (P less than 0.01). In the control group AKBR was maintained thereafter at near control value of 1.0 with a significant decrease in serum lactate concentration in spite of marked hypotension. T3 infusion at a rate of 1 microgram/kg/hr elevated the AKBR but did not elevate MAP. Vasopressin infusion at a rate of 0.1 U/kg/hr sustained AKBR and elevated MAP significantly at 1 hr after administration but tended to decrease thereafter. Combined administration of T3 and ADH elevated the AKBR to about 2.0, and MAP was restored to near-normal level. Other parameters such as glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, and lactic dehydrogenase, reflecting liver cell injury and serum creatinine, and blood urea nitrogen as renal function, were maintained within normal range. These results indicate that combined T3 and vasopressin administration has a beneficial synergistic effect on both hepatic energy metabolism and systemic hemodynamics without any detrimental influence to other conventional parameters. Therefore, it is suggested that this combined administration may contribute to the management of potential multiorgan donors.
Washida
M
M
Second Department of Surgery, Faculty of Medicine, Kyoto University, Japan.
Okamoto
R
R
Manaka
D
D
Yokoyama
T
T
Yamamoto
Y
Y
Ino
K
K
Yamamoto
N
N
Osaki
N
N
Shimahara
Y
Y
Yamaoka
Y
Y
D000818:Animals; D001926:Brain Death / Q000503:physiopathology*; D004285:Dogs; D004359:Drug Therapy, Combination; D004734:Energy Metabolism / Q000187:drug effects*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D007657:Ketone Bodies / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D014284:Triiodothyronine / Q000008:administration & dosage* / Q000097:blood; D014667:Vasopressins / Q000008:administration & dosage* / Q000097:blood
D007657:Ketone Bodies; D014284:Triiodothyronine; D014667:Vasopressins